OncoMethylome Sciences to Perform MGMT Testing in Roche Phase III Study of Avastin for Glioblastoma
OncoMethylome's Technology is being used in Roche Clinical Trial Program with Avastin
OncoMethylome Sciences announced that it has entered into an agreement with F. Hoffmann-La Roche Ltd., of Basel Switzerland, for MGMT gene promoter methylation testing in a Phase III clinical trial for the use of Avastin in newly diagnosed (glioblastoma [GBM]) brain tumors.
This trial will compare the current standard-of-care therapy, which is concurrent chemoradiation and adjuvant temozolomide "TMZ" (Temodar, Schering-Plough), with the standard-of-care plus bevacizumab (Avastin, Roche). All patients will be randomized to TMZ and radiotherapy or TMZ, radiotherapy and bevacizumab. OncoMethylome Sciences will receive payments for performing MGMT testing, using their patented Methylation-Specific PCR (MSP) technology, on all patients enrolled in this trial.
Mr. Luc Segers, Senior Director Business Development at OncoMethylome commented, "We are very pleased that MGMT testing will be incorporated into this study, once again demonstrating the market interest in identifying biomarkers that will lead to more personalized healthcare."
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Clinical Trials Initiated and Significant Milestone Reached in the Collaboration Between Karo Bio and Merck & Co., Inc.
Evolva completes Abunda acquisition
Tripos Announces LeadScreen™ 2002, Pre-Formatted Screening Compound Set to Accelerate Drug Discovery by Biotechs
Inion introduces its First Biodegradable Spinal Implant in Europe - CE Mark received for S-1TM Anterior Cervical Fixation System
Dr Barry Buckland Joins the Mucosis Supervisory Board
Beckman Coulter Announces the Creation of Beckman Coulter Genomics - New Company Offers Comprehensive Genomic Services
Scientists remove amyloid plaques from brains of live animals with Alzheimer's disease - New research in the FASEB Journal suggests that manipulation of the brain's own immune cells with IL-6 could lead to reversal of Alzheimer's disease pathology
